QC
KRYS icon

Quent Capital’s Krystal Biotech KRYS Stock Holding History

Quent Capital’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.6K Hold
34
– – ﹤0.01% 1190
2026
Q1 		$8.78K Hold
34
– – ﹤0.01% 1183
2025
Q4 		$8.38K Hold
34
– – ﹤0.01% 1188
2025
Q3 		$6K Buy
+34
New +$5.09K ﹤0.01% 1121
2025
Q2 		– Sell
-59
Closed -$10.6K – 807
2025
Q1 		$10.6K Buy
+59
New +$9.92K ﹤0.01% 894

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Quent Capital's KRYS Position: Q2 2026 in Review

Quent Capital held its Krystal Biotech (KRYS) position steady in Q2 2026 at 34 shares worth $12.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1190.

Quent Capital first reported a position in KRYS in Q1 2025 and has held it in 5 quarters since. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Quent Capital held 34 shares of Krystal Biotech worth $12.6K as of Q2 2026.
  • Quent Capital left its Krystal Biotech share count unchanged in Q2 2026.
  • Krystal Biotech made up ﹤0.01% of Quent Capital's portfolio in Q2 2026, its #1190 holding.
  • Quent Capital first reported a position in Krystal Biotech in Q1 2025 and has held it in 5 quarters since.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Quent Capital's 13F filing for Q2 2026, filed 7 Aug 2026.